Literature DB >> 27893178

Comprehensive genetic characterization of rosette-forming glioneuronal tumors: independent component analysis by tissue microdissection.

Yohei Kitamura1,2, Takashi Komori3, Makoto Shibuya4, Kentaro Ohara5,6, Yuko Saito7, Saeko Hayashi2,8, Aya Sasaki9, Eiji Nakagawa10, Ryosuke Tomio2, Akiyoshi Kakita11, Masashi Nakatsukasa1, Kazunari Yoshida2, Hikaru Sasaki2.   

Abstract

A rosette-forming glioneuronal tumor (RGNT) is a rare mixed neuronal-glial tumor characterized by biphasic architecture of glial and neurocytic components. The number of reports of genetic analyses of RGNTs is few. Additionally, the genetic background of the unique biphasic pathological characteristics of such mixed neuronal-glial tumors remains unclear. To clarify the genetic background of RGNTs, we performed separate comprehensive genetic analyses of glial and neurocytic components of five RGNTs, by tissue microdissection. Two missense mutations in FGFR1 in both components of two cases, and one mutation in PIK3CA in both components of one case, were detected. In the latter case with PIK3CA mutation, the additional FGFR1 mutation was detected only in the glial component. Moreover, the loss of chromosome 13q in only the neurocytic component was observed in one other case. Their results suggested that RGNTs, which are tumors harboring two divergent differentiations that arose from a single clone, have a diverse genetic background. Although previous studies have suggested that RGNTs and pilocytic astrocytomas (PAs) represent the same tumor entity, their results confirm that the genetic background of RGNTs is not identical to that of PA.
© 2016 International Society of Neuropathology.

Entities:  

Keywords:  CGH; FGFR1; PIK3CA; genetics; mixed neuronal-glial tumor; rosette-forming glioneuronal tumor

Mesh:

Substances:

Year:  2017        PMID: 27893178     DOI: 10.1111/bpa.12468

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  4 in total

1.  Molecular analyses of rosette-forming glioneuronal tumor of the midbrain tegmentum: A report of two cases and a review of the FGFR1 status in unusual tumor locations.

Authors:  Hajime Handa; Ichiyo Shibahara; Yoshiko Nakano; Madoka Inukai; Sumito Sato; Takuichiro Hide; Junko Hirato; Takako Yoshioka; Koichi Ichimura; Toshihiro Kumabe
Journal:  Surg Neurol Int       Date:  2022-05-20

2.  Spinal rosette-forming glioneuronal tumor: A case report.

Authors:  Shuji Hamauchi; Mishie Tanino; Kazutoshi Hida; Toru Sasamori; Shunsuke Yano; Shinya Tanaka
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

Review 3.  Rosette-forming glioneuronal tumor: an illustrative case and a systematic review.

Authors:  Caleb P Wilson; Arpan R Chakraborty; Panayiotis E Pelargos; Helen H Shi; Camille K Milton; Sarah Sung; Tressie McCoy; Jo Elle Peterson; Chad A Glenn
Journal:  Neurooncol Adv       Date:  2020-09-09

4.  Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.

Authors:  Calixto-Hope G Lucas; Rohit Gupta; Pamela Doo; Julieann C Lee; Cathryn R Cadwell; Biswarathan Ramani; Jeffrey W Hofmann; Emily A Sloan; Bette K Kleinschmidt-DeMasters; Han S Lee; Matthew D Wood; Marjorie Grafe; Donald Born; Hannes Vogel; Shahriar Salamat; Diane Puccetti; David Scharnhorst; David Samuel; Tabitha Cooney; Elaine Cham; Lee-Way Jin; Ziad Khatib; Ossama Maher; Gabriel Chamyan; Carole Brathwaite; Serguei Bannykh; Sabine Mueller; Cassie N Kline; Anu Banerjee; Alyssa Reddy; Jennie W Taylor; Jennifer L Clarke; Nancy Ann Oberheim Bush; Nicholas Butowski; Nalin Gupta; Kurtis I Auguste; Peter P Sun; Jarod L Roland; Corey Raffel; Manish K Aghi; Philip Theodosopoulos; Edward Chang; Shawn Hervey-Jumper; Joanna J Phillips; Melike Pekmezci; Andrew W Bollen; Tarik Tihan; Susan Chang; Mitchel S Berger; Arie Perry; David A Solomon
Journal:  Acta Neuropathol Commun       Date:  2020-08-28       Impact factor: 7.801

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.